Welcome to the official EE-ASI homepage!
Whether you are a patient, a scientist, a company or a foundation involved in the fight against Type 1 Diabetes, we hope that you can find here all information you need about our European Commission - supported programme “EE-ASI”, aiming at clinically testing an innovative vaccine against Type 1 Diabetes. You will find our contact details for any additional question.
![]() |
To download EE-ASI presentation leaflet, please click here |
Our Enhanced Epidermal – Antigen Specific Immunotherapy (EE-ASI) system represents an innovative approach to ASI created by combining technologies brought by our academic and 2 SME partners. A beta cell target T cell epitope (proinsulin C19-A3) will be combined with the tolerogenic cytokine IL-10 and targeted to antigen presenting cells via gold nanoparticles and delivery into the very superficial layers of the skin using microneedles. Validation of manufacture, in vitro and in vivo preclinical efficacy will be demonstrated followed by a phase 1 clinical trial to confirm safety in humans.
We anticipate that the EE-ASI system will be less costly, more effective and more acceptable to patients in improving glycaemic control than exogenous insulin replacement. Intellectual property, regulatory and ethical issues will be carefully addressed in order to maximise exploitation of this integrated system for the benefit of the SMEs.